Announced Tue, 28 Apr · 18:51 IST
Sanofi India board changes; Q4 FY26 profit at Rs 1,026M
Management Changes View source PDF
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.6%1-day move
₹3460.10
prior close
₹3468.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.2+0.3+0.4-0.1-1.6-1.7-1.6-1.8-2.0-5.4-7.8-11.1-3.0—
Up moveDown movePending
AI summary
Sanofi India's board approved Q4 FY26 unaudited results: revenue Rs 4,723M (vs Rs 5,359M YoY), profit after tax Rs 1,026M (vs Rs 1,195M YoY); EPS Rs 44.55. Independent Directors Aditya Narayan and Usha Thorat completed their tenure on April 29. Rahul Bhatnagar appointed Chairman from April 30. Board committees reconstituted. Insulin portfolio posted double-digit growth for the second straight quarter.
Likely market impact
Routine tenure completions, no governance concerns. Q4 profit up 66% sequentially but down 14% YoY due to partnership transition impact. Insulin franchise remains strong.